Ocata Therapeutics (NASDAQ: OCAT) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
This table compares Ocata Therapeutics and Rigel Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings for Ocata Therapeutics and Rigel Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Rigel Pharmaceuticals has a consensus price target of $6.75, suggesting a potential upside of 209.63%. Given Rigel Pharmaceuticals’ higher possible upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than Ocata Therapeutics.
Valuation and Earnings
This table compares Ocata Therapeutics and Rigel Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Rigel Pharmaceuticals||$10.34 million||26.23||-$67.71 million||($0.69)||-3.16|
Ocata Therapeutics has higher revenue, but lower earnings than Rigel Pharmaceuticals.
Institutional and Insider Ownership
88.6% of Rigel Pharmaceuticals shares are held by institutional investors. 5.2% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Rigel Pharmaceuticals beats Ocata Therapeutics on 6 of the 8 factors compared between the two stocks.
Ocata Therapeutics Company Profile
Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
Rigel Pharmaceuticals Company Profile
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The Company’s clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted a new drug application (NDA) to the United States food and drug administration (FDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, the Company has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. The Company is engaged in conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.
Receive News & Ratings for Ocata Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.